Prot # CMX001-301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic

Project: Research project

Project Details

StatusFinished
Effective start/end date9/27/139/27/18

Funding

  • PRA Health Sciences (CMX001-301)
  • Chimerix, Inc. (CMX001-301)